{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:13:30Z","timestamp":1790007210009,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jaad.2016.01.020","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T13:15:24Z","timestamp":1456665324000},"page":"835-840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP)"],"prefix":"10.1016","volume":"74","author":[{"given":"Alexander","family":"Maley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilyse","family":"Haberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9802-4144","authenticated-orcid":false,"given":"Robert","family":"Swerlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhairavi","family":"Kharod-Dholakia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.01.020_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.01.020_bib2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.01.020_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2012.10.018","article-title":"Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature","volume":"68","author":"Shetty","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.01.020_bib4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/14712598.2015.1046833","article-title":"Rituximab preserves vision in ocular mucous membrane pemphigoid","volume":"15","author":"R\u00fcbsam","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaad.2016.01.020_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ophtha.2003.03.001","article-title":"Mucous membrane pemphigoid and pseudopemphigoid","volume":"111","author":"Thorne","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaad.2016.01.020_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","article-title":"Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts","volume":"72","author":"Murrell","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.01.020_bib7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.01.020_bib8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.01.020_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2340\/00015555-0560","article-title":"Successful treatment of mucous membrane pemphigoid with the anti-CD20 antibody rituximab","volume":"89","author":"Schumann","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.01.020_bib10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses\u00a0and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.01.020_bib11","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1468-3083.2010.03889.x","article-title":"Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients","volume":"25","author":"Lourari","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.01.020_bib12","first-page":"4","article-title":"Rituximab therapy of recalcitrant bullous dermatoses","volume":"29","author":"Wollina","year":"2008","journal-title":"J Dermatol Case Rep"},{"key":"10.1016\/j.jaad.2016.01.020_bib13","first-page":"731","article-title":"Successful adjuvant treatment of recalcitrant, mucous membrane pemphigoid with anti-CD20 antibody rituximab","volume":"6","author":"Taverna","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2016.01.020_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/bjo.2007.129510","article-title":"The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement","volume":"93","author":"Ross","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaad.2016.01.020_bib15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2013.01.046","article-title":"Treatment of mucous membrane pemphigoid with rituximab","volume":"69","author":"Heelan","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.01.020_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","article-title":"A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","volume":"14","author":"Ahmed","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2016.01.020_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2133.2011.10658.x","article-title":"Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy","volume":"166","author":"Feldman","year":"2012","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216000724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216000724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:39:25Z","timestamp":1759271965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216000724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0190962216000724"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.01.020","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP)","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}